[Enantiomers: a new problem in pharmacotherapy of depression?].
Enantiomers as a optically active forms of drugs now have a big impact on most areas of pharmacotherapy. They arouse a large interest in the field of psychiatry and especially in the treatment of depression. This is due to the fact that enantiomers (chiral forms) of many drugs may have a different pharmacokinetic, pharmacological or pharmacogenetic profiles. Therefore, in many cases the use of a single enantiomer of the drug may have huge advantages over previously used forms and lead to strong improvement of the current treatments. An example is the stereoselective property of such a psychotropic drug fluoxetine as belonging to a group of selective serotonin reuptake inhibitors (SSRI).